Back to results
US 2021/0275589 A1Published application
Co-receptor systems for treating infectious diseases
OwnerMing Zeng, Lu Chen +3inventors
InventorsMing Zeng, Lu Chen, Shu Wu, Lili Chen, Xun Liu
Life of this patent
Estimating the term…
Abstract
Immune cells (such as T cells) comprising a chimeric receptor (CR), a chimeric co-receptor (CCOR), and/or a co-receptor (COR) are provided.
Claims58
An engineered immune cell comprising:
- a) a chimeric receptor (CR) comprising:
- i) a CR antigen binding domain specifically recognizing a CR target antigen;
- ii) a CR transmembrane domain, and iii) an intracellular CR signaling domain;
- and
- b) a chimeric co-receptor (CCOR) comprising:
- i) a CCOR antigen binding domain specifically recognizing a CCOR target antigen;
- ii) a CCOR transmembrane domain;
- and iii) an intracellular CCOR co-stimulatory domain,
- wherein the CR target antigen is CCR5 or CXCR4 and the CCOR target antigen is CD4, or wherein the CR target antigen is CD4 and the CCOR target antigen is CCR5 or CXCR4.
6 more elements
An engineered immune cell comprising:
- a chimeric receptor (CR) comprising:
- i) a CR antigen binding domain specifically recognizing a CR target antigen;
- ii) a CR transmembrane domain, and iii) an intracellular CR signaling domain,
- wherein the CR target antigen is selected from the group consisting of CCR5, CXCR4 and CD4.
1 more element
An engineered immune cell comprising:
- a) a first nucleic acid encoding a chimeric receptor (CR), wherein the CR comprises:
- i) a CR antigen binding domain specifically recognizing a CR target antigen;
- ii) a CR transmembrane domain, and iii) an intracellular CR signaling domain;
- and
- b) second nucleic acid encoding a chimeric co-receptor (CCOR), wherein the CCOR comprises:
- i) a CCOR antigen binding domain specifically recognizing a CCOR target antigen;
- ii) a CCOR transmembrane domain;
- and iii) an intracellular CCOR co-stimulatory signaling domain;
- wherein the CR target antigen is CCR5 or CXCR4 and the CCOR target antigen is CD4, or wherein the CR target antigen is CD4 and the CCOR target antigen is CCR5 or CXCR4.
6 more elements
An engineered immune cell comprising:
- a nucleic acid encoding a chimeric receptor (CR), wherein the CR comprises:
- i) a CR antigen binding domain specifically recognizing a CR target antigen;
- ii) a CR transmembrane domain, and iii) an intracellular CR signaling domain,
- wherein the CR target antigen is selected from the group consisting of CCR5, CXCR4 and CD4.
1 more element
The method of claim49, further comprising:
- c) introducing into the population of immune cells a second nucleic acid encoding the CCOR.
The method of claim50, further comprising introducing into the population of immune cells one or more nucleic acids encoding one or more CORs.
Dependencies are inferred from the claim text.